申请人:THE WELLCOME FOUNDATION LIMITED
公开号:EP0370740A1
公开(公告)日:1990-05-30
The present invention is concerned with compounds of formula (I)
wherein
m is 0 or 1;
W is hydrogen, a C1-16 straight, branched, or cyclic alkyl group, or a C2 -16 straight, branched, or cyclic alkenyl or alkynyl group, or
Ph(CH2)n- where Ph is phenyl and n is an integer of from 0 to 2, the phenyl group being optionally substituted by one or more atoms or groups independently selected from halogen, hydroxy, nitro, C1-4 alkoxy and C1 -4 alkyl wherein one or more of the hydrogen atoms in said alkyl group is optionally replaced by halogen, or
R1 NHCO- where R1 is hydrogen or a C1-6 alkyl group, or
R2CONH- where R2 is hydrogen or a C1-6 alkyl group;
X is -(CH2)PNHCO H,
where p is an integer of from 0 to 2, -NHCONH H2,
-CO H, -NHCO H2, -NHCO ,
-CS H, -NHCS H, -NHC(:NH) H,
-NHC(:NCN) H, -NHC(:CHCN) H,
-NHC(:CHN02) H, or -CH(A)CO H
where A is halogen;
Y is -(CH2)q, where q is an integer of from 1 to 3, or -CH = CH- (E or Z);
Z is a C1 -6 alkyl group optionally substituted by one or more independently selected polar groups; and ring A is optionally substituted by one or more atoms or groups independently selected from halogen, hydroxy, nitro, C1 -4 alkoxy and C1-4 alkyl wherein one or more of the hydrogen atoms in said alkyl group is optionally replaced by halogen;
provided said compound of formula (I) is not N-2-[(4-methylphenyl)methyl]phenyl}acetamide or α-(p-tolyl)-o-cresol carbanilate;
and salts, solvates and physiologically functional derivatives thereof, processes for the preparation of these compounds, pharmaceutical formulations containing them and their use in medicine.
本发明涉及式(I)化合物
其中
m 是 0 或 1;
W 是氢、C1-16 直链、支链或环状烷基或 C2 -16 直链、支链或环状烯基或炔基,或
Ph(CH2)n- 其中 Ph 是苯基,n 是 0 至 2 的整数,苯基可选择被一个或多个独立选自卤素、羟基、硝基、C1-4 烷氧基和 C1-4 烷基的原子或基团取代,其中所述烷基中的一个或多个氢原子可选择被卤素取代,或
R1 NHCO- 其中 R1 为氢或 C1-6 烷基,或
R2CONH- 其中 R2 是氢或 C1-6 烷基;
X 是-(CH2)PNHCO H、
其中 p 是 0 至 2 的整数,-NHCONH H2、
-CO H、-NHCO H2、-NHCO 、
-CS H,-NHCS H,-NHC(:NH)H、
-NHC(:NCN)H,-NHC(:CHCN)H、
-NHC(:CHN02)H,或-CH(A)CO H
其中 A 为卤素;
Y 是-(CH2)q,其中 q 是 1 至 3 的整数,或 -CH = CH- (E 或 Z);
Z 是任选被一个或多个独立选择的极性基团取代的 C1 -6 烷基;且环 A 任选被一个或多个独立选自卤素、羟基、硝基、C1 -4 烷氧基和 C1-4 烷基的原子或基团取代,其中所述烷基中的一个或多个氢原子任选被卤素取代;
前提是所述式 (I) 化合物不是 N-2-[(4-甲基苯基)甲基]苯基}乙酰胺或 α-(对甲苯基)-邻甲酚甲酰苯胺;
及其盐类、溶剂和生理功能衍生物,这些化合物的制备工艺,含有这些化合物的药物制剂及其在医学中的应用。